- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Amarin Corporation PLC ADR (AMRN)
Track the Amarin ADR share price today and view real-time AMRN share price data, including charts, technicals, and key financials. View the AMRN premarket stock price ahead of the market session or assess the after hours quote. Explore AMRN stock price movements, trading volume, and market activity across the NASDAQ exchange.
What Is the Amarin ADR Stock Price Today?
The Amarin ADR stock price today is 12.350.
What Is the Stock Symbol for Amarin ADR?
The stock symbol for Amarin ADR is ""AMRN.""
What Stock Exchange Does Amarin ADR Trade On?
Amarin ADR is listed and trades on the NASDAQ stock exchange.
Is Amarin ADR a Good Stock to Buy?
Determining whether Amarin ADR or any stock is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the AMRN quote. (ISIN: US0231114044)
What Is the Amarin ADR Stock Price Today?
The Amarin ADR stock price today is 12.350.
What Is the Stock Symbol for Amarin ADR?
The stock symbol for Amarin ADR is ""AMRN.""
What Stock Exchange Does Amarin ADR Trade On?
Amarin ADR is listed and trades on the NASDAQ stock exchange.
Is Amarin ADR a Good Stock to Buy?
Determining whether Amarin ADR or any stock is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the AMRN quote. (ISIN: US0231114044)
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
12.310
13.020
52 wk Range
12.310
20.900
Trading near 52-week Low
1/2
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
12.31013.020
52 wk Range
12.31020.900
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
AMRN Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Sell
Price Target
12.500
Upside
+1.21%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
RSI suggests the stock is in oversold territory
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell
Analyst Ratings
0 Buy
0 Hold
2 Sell
Ratings:
2 analysts
Overall Consensus
Sell
Analysts 12-Month Price Target:
Average 12.500
(+1.21% Upside)
Amarin Corporation PLC ADR Earnings Call Summary for Q2/2026
- Q2 revenue fell 42% to $42.2M from $72.7M, largely due to absence of prior year's $25M Recordati upfront payment and European model shift.
- Achieved third consecutive quarter of positive operating cash flow at $7M; cash rose to $314.6M with zero debt and $70M annual cost savings.
- U.S. VASCEPA prescriptions grew 14% YoY with market share rising to 48%; European in-market demand surged 69% under Recordati partnership.
- Management expects positive full-year 2026 cash flow and stable U.S. volumes through year-end; maintains key payer exclusives through 2026.
- Completed global restructuring program; executives call Q2 an 'inflection point' for dual commercial strategy combining U.S. direct sales with partnered international model.
Last Updated: 29/07/2026, 10:50 pm
Read Full TranscriptEarnings
Latest Release
29/07/2026
EPS / Forecast
-0.40 / -0.17
Revenue / Forecast
42.21M / --
Compare AMRN to Peers and Sector
Metrics to compare | AMRN | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipAMRNPeersSector | |
|---|---|---|---|---|
P/E Ratio | −9.6x | −2.2x | −0.3x | |
PEG Ratio | −0.13 | −0.23 | 0.00 | |
Price/Book | 0.6x | 1.4x | 2.6x | |
Price / LTM Sales | 1.4x | 3.1x | 3.0x | |
Upside (Analyst Target) | 1.2% | 226.8% | 58.6% | |
Fair Value Upside | Unlock | 13.8% | 8.4% | Unlock |
Amarin Corporation plc, a pharmaceutical company, engages in the commercialization and development of therapeutics for the treatment of cardiovascular diseases in the United States, Europe, and internationally. It offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. The company sells its products principally through wholesalers, selected regional wholesalers, and retail and mail order pharmacy providers. It has a collaboration with Mochida Pharmaceutical Co., Ltd. to develop and commercialize drug products and indications based on the active pharmaceutical ingredient in Vascepa, the omega-3 acid, EPA. The company was formerly known as Ethical Holdings plc and changed its name to Amarin Corporation plc in 1999. Amarin Corporation plc was incorporated in 1989 and is headquartered in Dublin, Ireland.
Ownership
Ownership Overview
Top Holders
People Also Watch
FAQ
What Is the Amarin ADR (AMRN) Stock Price Today?
The Amarin ADR stock price today is 12.350 USD.
What Stock Exchange Does Amarin ADR Trade On?
Amarin ADR is listed and trades on the Nasdaq Stock Exchange.
What Is the Stock Symbol for Amarin ADR?
The stock symbol for Amarin ADR is "AMRN."
What Is the Amarin ADR Market Cap?
As of today, Amarin ADR market cap is 268.680M USD.
What Is Amarin ADR's Earnings Per Share (TTM)?
The Amarin ADR EPS (TTM) is -1.299.
From a Technical Analysis Perspective, Is AMRN a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
How Many Times Has Amarin ADR Stock Split?
Amarin ADR has split 3 times.
How Many Employees Does Amarin ADR Have?
Amarin ADR has 80 employees.
What is the current trading status of Amarin ADR (AMRN)?
As of 03/10/2026, Amarin ADR (AMRN) is trading at a price of 12.350 USD, with a previous close of 12.350 USD. The stock has fluctuated within a day range of 12.310 USD to 13.020 USD, while its 52-week range spans from 12.310 USD to 20.900 USD.
What Is Amarin ADR (AMRN) Price Target According to Analysts?
The average 12-month price target for Amarin ADR is 12.500 USD, with a high estimate of 13 USD and a low estimate of 12 USD. 0 analysts recommend buying the stock, while 2 suggest selling, leading to an overall rating of Sell. The stock has an +1.21% Upside potential.
What Is the AMRN Premarket Price?
AMRN's last pre-market stock price is 13.000 USD. The pre-market share volume is 480.000, and the stock has decreased by 0.280, or 2.200%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.